Abstract:LBA2 Background: Standard of care (SOC) for resectable, macroscopic stage III melanoma is therapeutic lymph node dissection (TLND) followed by adjuvant (adj) therapy with nivolumab (NIVO), pembrolizumab (PEM) or, in BRAFmut melanoma, dabrafenib + trametinib (DAB/TRAM). The recent phase 2 SWOG S1801 trial showed superior event-free survival (EFS) of neoadjuvant (neoadj) + adj PEM as compared to adj PEM (estimated 2y-EFS 72% vs 49%). Additional phase 2 trials demonstrated safety and high efficacy (77-80% 2y-EFS) of neoadj ipilimumab (IPI) 1 mg/kg + nivolumab (NIVO) 3 mg/kg, providing the rationale for testing neoadj IPI + NIVO against SOC in a phase 3 trial. Methods: In this investigator initiated, international phase 3 trial, resectable, macroscopic, nodal stage III melanoma pts, naive to ICI and BRAFi/MEKi, were randomized to receive 2 cycles of neoadj IPI 80mg + NIVO 240mg (q3w) followed by TLND, and in case of not achieving a major pathologic response (MPR) adj DAB/TRAM (150mg BID/2mg QD; 46 wks) or 11 cycles of adj NIVO (480mg; q4w; if BRAFwt) versus TLND followed by 12 cycles of adj NIVO (480mg; q4w). The primary endpoint EFS is defined as time from randomization until progression, recurrence or death due to melanoma or treatment, and was assessed using a Cox regression model. An interim analysis using a 2-sided alpha of 0.1% (Haybittle-Peto stopping rule) was planned per protocol after completing recruitment. Results: Between Aug 2021 and Dec 2023, 423 pts were randomly assigned; 212 pts to the neoadj arm and 211 to the adj arm. At data cutoff on January 12, 2024, with a median FU of 9.9 mos, significantly less events occurred in the neoadj arm vs the adj arm (28 vs 72), with HR 0.32 (99.9% CI 0.15-0.66, p<0.0001) and estimated 12-mo EFS rates of 83.7% (99.9% CI 73.8-94.8) vs 57.2% (99.9% CI 45.1-72.6) favoring the neoadj arm. In the subgroup of BRAFmut melanoma, estimated EFS rates were 83.5% and 52.1%, and in BRAFwt 83.9% and 62.4% for neoadj versus adj respectively. 58.0% of pts in the neoadj arm had an MPR, 8.0% a path partial-response (pPR), 26.4% a path non-response (pNR), 2.4% had progression before surgery and 5.2% were not reported (95% centrally reviewed). The 12-mo RFS rates according to path response were 95.1% for MPR, 76.1% for pPR and 57.0% for pNR. Systemic treatment related adverse events (AE) grade ≥3 were seen in 29.7% and 14.7% in the neoadj and adj arm; 1 pt died due to toxicity in adj arm (pneumonitis). Surgery related grade ≥3 AEs were reported in 14.6% and 14.4% respectively. Conclusions: NADINA is the first phase 3 trial that evaluates neoadj immunotherapy against SOC in melanoma, and is also the first phase 3 trial in oncology evaluating a neoadj regimen consisting of immunotherapy alone. Neoadj IPI+NIVO followed by response-driven adj treatment results in statistically significant improved EFS compared to adj NIVO and should be considered a new SOC treatment in macroscopic stage III melanoma. Clinical trial information: NCT04949113 .

Neo-Adjuvant Therapy for Metastatic Melanoma

Neoadjuvant Therapy in Advanced Melanoma.

Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis.

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing

Neoadjuvant therapy for melanoma: past, present, and future

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma

Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF V600 -mutant resectable melanoma: the randomized phase 2 NeoTrio trial

Neoadjuvant therapy for resectable melanoma

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma

Neoadjuvant therapy for melanoma: A critical appraisal

Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.

Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment

Adjuvant immunotherapy for melanoma patients: progress and opportunities

Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.

Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma